Treatment of chronic non-infectious uveitis and scleritis

Swiss Med Wkly. 2019 Mar 10;149:w20025. doi: 10.4414/smw.2019.20025. eCollection 2019 Feb 25.


Ocular inflammations such as uveitis and scleritis can lead to significant visual impairment if not treated properly. To limit potentially sight-threatening complications, good control of the inflammation in the acute phase is necessary. Corticosteroids have been the mainstay of ocular therapies for many years, but high doses of corticosteroids, which are required to maintain quiescence in severe uveitis, can be associated with many systemic and ocular complications. In order to limit steroid side-effects, classic immunosuppressant and immunobiologic agents have been widely used as steroid-sparing agents. In this review, we summarise the immunosuppressive drug therapy utilised in the treatment of ocular inflammatory diseases.

Publication types

  • Systematic Review

MeSH terms

  • Adrenal Cortex Hormones / adverse effects
  • Adrenal Cortex Hormones / therapeutic use
  • Azathioprine / therapeutic use*
  • Cyclosporine / therapeutic use*
  • Enzyme Inhibitors / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Methotrexate / therapeutic use*
  • Mycophenolic Acid / therapeutic use
  • Scleritis / drug therapy*
  • Uveitis / drug therapy*


  • Adrenal Cortex Hormones
  • Enzyme Inhibitors
  • Immunosuppressive Agents
  • Cyclosporine
  • Mycophenolic Acid
  • Azathioprine
  • Methotrexate